NCT05513742 (COMPANION-003) is a Phase 2 clinical trial of CTX-009 in Metastatic Colorectal Cancer, sponsored by Compass Therapeutics.

Who is sponsoring NCT05513742?

NCT05513742 is sponsored by Compass Therapeutics.

What drugs are being tested in NCT05513742?

Interventions in NCT05513742: CTX-009.

What condition does NCT05513742 study?

NCT05513742 studies Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer.

Is NCT05513742 still recruiting?

NCT05513742 is currently completed. Last updated 17 April 2026.

Last reviewed 2026-04-17 · How we verify

NCT05513742: COMPANION-003

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer

Completed Phase 2 Last updated 17 April 2026

What this trial tests

Phase 2 trial testing CTX-009 in Metastatic Colorectal Cancer in 49 participants. Completed in 15 May 2025.

Timeline

8 December 2022

Primary endpoint
28 April 2025

15 May 2025

Quick facts

Lead sponsor	Compass Therapeutics
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	49
Start date	8 December 2022
Primary completion	28 April 2025
Estimated completion	15 May 2025
Sites	7 locations across United States

Drugs / interventions tested

CTX-009 — full drug profile →

Conditions studied

Metastatic Colorectal Cancer — all drugs for Metastatic Colorectal Cancer →
Colon Cancer — all drugs for Colon Cancer →
Rectal Cancer — all drugs for Rectal Cancer →

Sponsor

Compass Therapeutics — full company profile →

Who can join

18 and older, any sex, with Metastatic Colorectal Cancer or Colon Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer. A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs.
Zhao Q, Zong H, Zhu P, Su C, et al · · 2024 · cited 25× · PMID 38254219 · DOI 10.1186/s40164-024-00474-x
Angiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice.
Yang S, Fang Y, Ma Y, Wang F, et al · · 2025 · cited 11× · PMID 40268524 · DOI 10.1002/ctm2.70313

Verify or expand the search:

Other trials of CTX-009

Trials testing the same drug.

NCT07392957 — Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma · Phase 1, PHASE2 · not yet recruiting
NCT06548412 — CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Bi · Phase 1, PHASE2 · recruiting

Other recruiting trials for Metastatic Colorectal Cancer

Currently open trials in the same condition.

NCT07416552 — A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) · Phase 1 · recruiting
NCT07314294 — Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients · Phase 2 · recruiting
NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
NCT06959550 — Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorect · Phase 2 · recruiting
NCT06808685 — Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie · recruiting

Other Compass Therapeutics trials

Trials by the same sponsor.

NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT03881488 — Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metasta · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05513742 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 1 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Compass Therapeutics
Last refreshed: 17 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05513742.